

Bod Australia Limited (ASX:BDA) is a developer, distributor and marketer of health products and supplements, with a focus on plant-based extracts including medicinal cannabis.

CAPITAL STRUCTURE

| | |
|-----------------------|-----------|
| ASX code | BDA |
| Shares on issue | 88.7m |
| Market Capitalisation | ~\$31.07m |

BOARD & MANAGEMENT

Mr Mark Masterson
Non-Executive Chairman

Ms Jo Patterson
Chief Executive Officer

Mr Akash Bedi
Non-Executive Director

Mr George Livery
Non-Executive Director

Mr Patrice Malard
Non-Executive Director

Mr Simon O'Loughlin
Non-Executive Director

Mr Stephen Thompson
Alternate Director

Mr Stephen Kelly
Company Secretary

CONTACT

Level 1, 377 New South Head Rd
Double Bay, NSW 2028

T +612 9199 5018
E info@bodaustralia.com.au

Optimised Board commences following shareholder approval

- **New Board members appointed following NewH² strategic investment - Bod now well positioned to pursue growth on multiple fronts**
- **Appointments include leading pharmaceutical executive Mark Masterson as Non-Executive Chairman and senior H&H Group executives Patrice Malard and Akash Bedi**
- **Expertise and networks will significantly strengthen Bod's ability to develop new products and expand internationally**

Sydney, Australia – 25 November 2019: Medicinal cannabis healthcare products company, Bod Australia Limited (“Bod”, the “Company”) (ASX: BDA) is pleased to advise that the Company’s streamlined Board and management team has commenced following shareholder approval which was received at its Annual General Meeting on 11 November 2019.

Following the meeting, Mr Mark Masterson was appointed as Non-Executive Chairman, replacing Mr George Livery. Mr Masterson boasts two decades of experience in the pharmaceutical and healthcare sectors. He began his career with Johnson & Johnson before joining global healthcare giant, Abbott Laboratories (NYSE: ABT, market capitalisation: US\$147.98Bn) where he held multiple senior positions. Mr Masterson also held the role of CEO with Australia’s largest private diagnostic imaging network, I-MED. Following the acquisition of I-MED, he was appointed Chairman of Medicines Australia.

Subsequent to his appointment, Mr Masterson has purchased 441,176 fully paid ordinary shares in Bod Australia Limited. An Appendix 3Y notifying this change of holding has been lodged separately to this announcement.

As part of Bod’s exclusive agreement with NewH², the innovation arm of H&H Group to commercialise the Company’s CBD products (refer ASX announcement: 19 July 2019), Bod appointed Mr Akash Bedi and Mr Patrice Malard as Non-Executive Directors.

Mr Bedi is Chief Strategy & Operations Officer at H&H Group. He is responsible for progressing strategy and business development opportunities within H&H Group, as well as leading strategic investments for NewH². He has considerable experience in global start up investment, as well as the integration of high growth companies and technologies.

Mr Malard boasts a storied career across four decades, culminating in senior roles with international agriculture and food focused companies. Mr Malard holds a PhD in microbial genetics and cell biology from the University of Lille in France and currently acts as Chief Technology Officer of H&H Group. He is also the General Manager of the H&H Group Technical Centre and Chairman of the H&H Group’s BINC Foundation.

The recent appointments leave Bod well positioned to capitalise on the commercialisation of its CBD products through its agreement with NewH² and subsequently H&H Group, as well as the rapid scale up of its pharmaceutical business division across Australia and international jurisdictions.

The Company advises that previous Executive Chairman, Mr George Livery has moved to Non-Executive Director role. Further, Mr Stephen Thompson will assume an Alternate Director position and Mr Simon Taylor has retired from the Board of Directors. The Board thanks Mr Taylor for his guidance and leadership, and wishes him well with future endeavours.

CEO Jo Patterson said: "Bod's recent appointments bring additional technical and strategic experience to the Company as it progresses growth across multiple business divisions. Mark, Akash and Patrice bring incredible experience across pharmaceuticals, M&A, product development and commercialisation, which will be imperative to Bod's next phase of growth.

"We look forward to leveraging their experience as the Company continues the commercialisation phase of its CBD products and grows its medicinal cannabis operations domestically and internationally."

- ENDS -

ABOUT BOD AUSTRALIA

Bod Australia Limited (ASX:BDA) is a developer, distributor and marketer of health and skincare products. Bod works with plant based extracts, with specific expertise in leveraging the health benefits associated with cannabis and hemp.

Bod is actively developing a range of over-the-counter and prescription products based on its unique, standardised, pharmaceutical grade cannabis extracts.

The Company has a large distribution footprint in Australia, selling prescription and OTC products to over 1,000 retail outlets, including pharmacies, retail stores and healthcare chains. The Company also has distribution agreements with two of Australia's largest pharmacy wholesalers providing it with access to over two thirds of the market. Bod is also actively building capability in key European markets that it witnesses near term growth prospects.

BODAUSTRALIA.COM

For more information please contact:

Jo Patterson
Chief Executive Officer
info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 431 271 538